Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Summary
Pharmaceutical giant Merck exceeded financial expectations for the quarter and raised its earnings forecast. The strong performance was driven by robust sales of its established cancer immunotherapy, alongside growing momentum from a newly developed injectable version of the medication.
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.